#AI and #GenAI have a vast potential to unlock high-value opportunities across the #pharmaceutical value chain - a key topic in PwC's Next in #pharma 2024:https://pwc.to/45Xc0Jj https://pwc.to/3S4Tg4N
Michael Müller-Bungart’s Post
More Relevant Posts
-
After what has been a challenging couple of years for the #lifesciences industry, many of the industry's leaders are showing promising signs of recovery, with robust product pipelines and gastronomical investments being committed to researching and developing new and existing treatments. Here, we've highlighted the top 10 #pharmaceutical companies expected to lead the way when it comes to R&D over the next couple of years, based on their projected R&D spend in 2026: https://phrmwb.com/4bZqk5t #researchanddevelopment #pharmaceuticalcompanies #pharma
To view or add a comment, sign in
-
Read it Now: https://bit.ly/3pp9j1P Going from exchanging non-serialized T3 data (Transaction History, Transaction Information, and Transaction Statement) to serialized T2 data (TI and TS) is a major operational shift. Learn how TraceLink can help! #pharmaceutical #supplychain #pharma #DSCSA
To view or add a comment, sign in
-
-
According to McKinsey & Company's research, the top five pharma companies have made more than 50 investments in #digitalhealth and formed twice as many partnerships in recent years, showing that digital health is where the future of the #pharmaceutical industry lies. Click to learn more: https://shorturl.at/gotKN #McKinsey
To view or add a comment, sign in
-
We’re delighted to release our latest Annual Report, which provides a summary of the projects, publications, multi-stakeholder workshops and Technical Fora from Regulatory and #HTA workstreams undertaken in 2023. The report also includes a focused look at our agency benchmarking metrics work over the years and the impact this has had within the #pharmaceutical landscape. Download the CIRS 2023 Annual Report >> https://lnkd.in/emJZzriT #RegulatoryScience #RegulatoryAffairs #reimbursement #HEOR
To view or add a comment, sign in
-
Read it Now: https://bit.ly/3pp9j1P Going from exchanging non-serialized T3 data (Transaction History, Transaction Information, and Transaction Statement) to serialized T2 data (TI and TS) is a major operational shift. Learn how TraceLink can help! #pharmaceutical #supplychain #pharma #DSCSA
To view or add a comment, sign in
-
-
Read it Now: https://bit.ly/3pp9j1P Going from exchanging non-serialized T3 data (Transaction History, Transaction Information, and Transaction Statement) to serialized T2 data (TI and TS) is a major operational shift. Learn how TraceLink can help! #pharmaceutical #supplychain #pharma #DSCSA
To view or add a comment, sign in
-
-
In the recent edition, The Progressive Leaders Fortifying the Future of Healthcare, The CIOLOOK magazine gladly features Megan Smyth, an inspiring leader and a Senior Team Leader at Almac Group, along with other dynamic leaders in Healthcare. Read More: https://cutt.ly/CepAyHM6 #almacgroup #InspiringLeaders #Pharmaceuticals #pharmaceuticalindustry #chemicalindustry #TechLeaders #womenleaders #technology #businessmagazine #ciolook
The Progressive Leaders Fortifying the Future of Healthcare, June 2024
https://ciolook.com
To view or add a comment, sign in
-
Despite new therapies achieving clinical success, external factors such as government efforts to contain healthcare costs and high capital costs, along with global geopolitical conflicts, have slowed investment appetite in the sector. Learn more on the prominent drugs and the current environment for pharmaceutical companies in a new report, "Challenges and the Future of Drug Delivery Systems." https://ow.ly/vlne30sCT4J #Pharmaceuticals #HealthcareInvestment #DrugDeliverySystems
To view or add a comment, sign in
-
-
Pharmafocus May is now live! 💊 Dive in for the latest news 📰 , as well as insights from 💉 , Angelini Pharma 🧠 and much more! #pharma #health #pharmaceutical #healthcare #pharmafocus #magazine https://lnkd.in/ep8Vrtbi
To view or add a comment, sign in
-
-
Operating at the heart of the innovation lifecycle, providing the actionable information and insights our clients need to make critical decisions with speed and certainty.
Despite new therapies achieving clinical success, external factors such as government efforts to contain healthcare costs and high capital costs, along with global geopolitical conflicts, have slowed investment appetite in the sector. Learn more on the prominent drugs and the current environment for pharmaceutical companies in a new report, "Challenges and the Future of Drug Delivery Systems." https://ow.ly/2V6y30sEQGi #Pharmaceuticals #HealthcareInvestment #DrugDeliverySystems
To view or add a comment, sign in
-